• PDI Inhibition Enhances Panobinostat Efficacy in Multiple My

  2026-05-10

  This study demonstrates that combining the PDI inhibitor LTI6426 with low-dose panobinostat significantly enhances anti-myeloma activity in preclinical models, while minimizing toxicity. The work identifies ER stress pathway effectors as candidate biomarkers, suggesting a promising avenue for optimizing HDAC inhibitor regimens in multiple myeloma.

• EPZ5676: DOT1L Inhibitor Workflows for MLL Leukemia Research

  2026-05-09

  EPZ5676 unlocks precision in MLL-rearranged leukemia research by enabling robust, reproducible inhibition of H3K79 methylation. This article explores practical assay workflows, advanced protocol parameters, and troubleshooting strategies that help scientists maximize the selectivity and potency of this leading DOT1L inhibitor.

• Jasplakinolide: Precision Actin Polymerization Inducer for A

  2026-05-08

  Jasplakinolide, supplied by APExBIO, offers researchers a high-affinity, membrane-permeable actin polymerization inducer enabling robust cytoskeletal dynamics studies. This article presents optimized workflows, troubleshooting guidance, and innovative assay applications that set Jasplakinolide apart for cell biology and translational research.

• Phenothiazines Enhance Macrophage Antibacterial Activity via

  2026-05-08

  The referenced study demonstrates that phenothiazines, including perphenazine, enhance macrophage antibacterial activity by inducing reactive oxygen species (ROS) production and autophagy. These findings highlight a host-directed therapeutic strategy with the potential to bypass conventional antimicrobial resistance, with implications for translational research in immunology and neuropharmacology.

• Belinostat (PXD101): Strategic Epigenetic Modulation in Canc

  2026-05-07

  This thought-leadership article delivers a mechanistic and translational roadmap for leveraging Belinostat (PXD101) in cancer research. By integrating rigorous experimental rationale, competitive intelligence, and state-of-the-art in vitro evaluation frameworks, it provides actionable guidance for translational scientists focused on histone deacetylase inhibition in bladder and prostate cancer models.

• Deferoxamine Mesylate: Advanced Workflows in Iron Chelation

  2026-05-07

  Deferoxamine mesylate stands out as an iron-chelating agent for precise modulation of iron metabolism, oxidative stress, and hypoxia signaling. This article delivers actionable protocols, troubleshooting insights, and comparative advantages for researchers leveraging Deferoxamine mesylate in translational oncology, wound healing, and ferroptosis studies.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-05-06

  This study identifies a new class of allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, with compound 8c demonstrating potent in vitro and in vivo efficacy relevant to metabolic, allergic, and cancerous conditions. The findings highlight the therapeutic potential of targeting PDK4 for diseases characterized by metabolic dysregulation and provide a validated scaffold for future drug development.

• Lipid Scrambling Suppresses Ferroptosis and Boosts Tumor Imm

  2026-05-06

  Yang et al. uncover TMEM16F-mediated lipid scrambling as a key suppressor of ferroptosis at the plasma membrane, demonstrating that its inhibition potentiates ferroptotic cell death and enhances tumor immune rejection. This work refines our understanding of cell death execution and suggests new strategies for combining ferroptosis modulation with immunotherapy.

• Pronase E Protease Mixture: Optimizing Biomedical Workflows

  2026-05-05

  Pronase E’s broad-spectrum protease activity streamlines even the most challenging protein sample preparation tasks, enhancing reproducibility in proteomics and molecular biology. This guide translates recent research breakthroughs into actionable protocols, troubleshooting tips, and advanced application strategies for maximizing your results with this versatile enzyme.

• Thiothixene and the New Frontier: Assay Design for Dual Neur

  2026-05-05

  Explore how Thiothixene, a typical antipsychotic agent, is redefining neuroimmune assay workflows through its dual action on dopamine signaling and efferocytosis. This article uniquely bridges genetic insights from schizophrenia research with advanced in vitro assay optimization.

• Organic Cation Transporter Response to Xenobiotics in Aedes

  2026-05-04

  Kennel and Rouhier’s study investigates how Aedes aegypti mosquitoes physiologically and transcriptionally respond to injected xenobiotic dyes, including Olsalazine Sodium. Their results reveal that while transporter gene expression is minimally altered, the chemical structure of xenobiotics significantly impacts excretion dynamics and mosquito mortality, offering new insights for vector control strategies.

• Perphenazine (SKU B6157): Data-Backed Solutions for Cell Ass

  2026-05-04

  This article provides scenario-driven, evidence-based workflow guidance for using Perphenazine (SKU B6157) in cell viability, proliferation, and cytotoxicity assays. Designed for biomedical researchers and lab technicians, it addresses reproducibility, protocol optimization, and vendor reliability—highlighting APExBIO’s Perphenazine as a data-driven choice for advanced neuropharmacology and host-pathogen research.

• Docetaxel in Translational Oncology: Mechanisms, Resistance,

  2026-05-03

  This thought-leadership article explores how Docetaxel’s microtubule stabilization mechanism underpins its efficacy in cancer chemotherapy research, with a special focus on the emerging challenge of chemoresistance driven by microbiome alterations. We integrate mechanistic insights, strategic guidance for researchers, and evidence-based discussion, including new findings on the NF-κB-IL6-STAT3 axis in resistance. By referencing leading literature and product intelligence, we position APExBIO’s Docetaxel as a cornerstone for advanced translational models, bridging mechanistic depth with experimental strategy.

• Organic Cation Transporters in Aedes aegypti: Response to Dy

  2026-05-02

  Kennel and Rouhier (2025) investigated how Aedes aegypti mosquitoes process xenobiotic dyes, focusing on the molecular and physiological responses to compounds such as Alizarin Yellow and Olsalazine Sodium. Their findings reveal that the chemical structure of xenobiotics, rather than changes in transporter gene expression, predominantly determines excretion dynamics and mortality, providing new insights into mosquito detoxification and control strategies.

• Perospirone Inhibits Kv1.5 Channels: Cardiovascular Implicat

  2026-05-01

  A recent study demonstrates that perospirone (SM-9018 free base), a second-generation antipsychotic, exerts previously unrecognized off-target inhibition of voltage-gated Kv1.5 potassium channels in coronary arterial smooth muscle cells. This finding expands the mechanistic understanding of perospirone and highlights potential cardiovascular considerations in its use for neuropsychiatric research models.

595 records 7/40 page Previous Next First page 上5页 678910 下5页 Last page